Key terms
About DRRX
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DRRX news
Mar 28
6:27am ET
H.C. Wainwright Keeps Their Hold Rating on Durect (DRRX)
Mar 27
4:03pm ET
Durect reports Q4 EPS (10c), consensus (33c)
Mar 25
8:00am ET
Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
Mar 05
6:29am ET
Durect (DRRX) Gets a Hold from H.C. Wainwright
Mar 04
7:14am ET
Durect, Charles River enter collaboration agreement for ALZET product line
No recent news articles are available for DRRX
No recent press releases are available for DRRX
DRRX Financials
Key terms
Ad Feedback
DRRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DRRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
